Logo Photocure ASA
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Employees
100
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
54.00NOK
Average target price
79.67NOK
Spread / Average Target
+47.53%

Quarterly revenue - Rate of surprise